These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16209214)

  • 1. [Diagnosis and treatment of early prostate cancer].
    Zhu G; Liu M; Wan B
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):693-6, 712. PubMed ID: 16209214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening and early detection for prostate cancer.
    Magoha GA
    East Afr Med J; 1997 Oct; 74(10):664-7. PubMed ID: 9529752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnosis and treatment of localized prostate cancer].
    Usami M; Arai Y
    Hinyokika Kiyo; 1996 Oct; 42(10):759-61. PubMed ID: 8951471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the diagnosis and management of prostate cancer.
    LaSpina M; Haas GP
    Can J Urol; 2008 Aug; 15 Suppl 1():3-13; discussion 13. PubMed ID: 18700060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is routine digital rectal examination required for the followup of prostate cancer?
    Warren KS; McFarlane JP
    J Urol; 2007 Jul; 178(1):115-9. PubMed ID: 17499293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Practice guideline 'Prostate cancer: diagnosis and treatment'].
    de Reijke TM; Battermann JJ; van Moorselaar RJ; de Jong IJ; Visser AP; Burgers JS
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1771-5. PubMed ID: 18754308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
    Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
    Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
    Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.
    Punnen S; Nam RK
    Surg Oncol; 2009 Sep; 18(3):192-9. PubMed ID: 19282170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
    J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S; Roobol MJ; Postma R; Gosselaar C; van der Kwast TH; Bangma CH; Schröder FH
    Eur Urol; 2006 Sep; 50(3):475-82. PubMed ID: 16713065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
    Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA testing and DRE, TRUS scanning with sector biopsy, improved histology, curative treatments, and active surveillance for prostate cancer: a success story for men's health.
    Smart R
    N Z Med J; 2008 Dec; 121(1287):57-68. PubMed ID: 19098969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Japanese guideline for prostate cancer screening.
    Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T
    Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.